The ACTIV-6 trial reports that people who took the drug for three days may have spent slightly less time feeling unwell with SARS-CoV-2, but fails to find differences in disease progression between the treatment and placebo groups.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?
The Scientist Creative Services Team in collaboration with Thermo Fisher Scientific | Nov 2, 2021
Edward Emmott will discuss mass spectrometry approaches to understand proteolysis during viral infection and their use in developing targeted strategies for COVID-19 treatment.
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
A sugar that’s less abundant in the blood of people with diabetes binds to SARS-CoV-2’s spike protein and disrupts the virus’s ability to fuse with cells.
A device smaller than two stacked decks of cards can reliably detect and discriminate between SARS-CoV-2 variants in spit in less than an hour with results that glow.
The Scientist spoke with Ohio State University microbiologist Matthew Sullivan about a recent expedition that identified thousands of RNA viruses from water samples and cataloged them into novel phylogenic groups.
A new presidential memorandum requires the Department of Health and Human Services to coordinate a government-wide push to generate a research action plan for the condition.
In addition to causing more frequent natural disasters, global warming can have long-term health effects, which range from heat stress to mosquito-borne disease.